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ABSTRACT 
Cell surface receptor tyrosine kinases (RTKs) role in cell signaling have been studied for decades 
and their role in cancer progression are undisputable. The insulin-like growth factor 1 receptor, 
IGF-1R, has been demonstrated to play a critical part in tumorigenesis; downregulation of the 
IGF-1R in tumor xenografts results in complete tumor regression. Previously, RTK research has 
focused on the canonical signaling pathways activated by ligand binding at the plasma 
membrane. However, strong evidence keeps emerging that several RTKs have a second 
functionally mechanism, inside the cell nucleus, where the receptors reside after ligand 
stimulation.  The aim of this thesis was to elucidate the function of recently discovered nuclear 
IGF-1R as well as to investigate its nuclear translocation pathway. Since it was previously shown 
that SUMOylation of the IGF-1R is essential for its nuclear translocation we also set out to 
investigate SUMO modification of the epidermal growth factor receptor (EGFR).  
 
In paper I, we present a functional role for nuclear IGF-1R in gene transcription. Inside the 
nucleus, IGF-1R functions as a co-activator to LEF-1/TCF transcription factor. Nuclear IGF-1R 
enhances transcription of cyclin D1 and axin2, and we show that it is enriched in the cyclin D1 
promoter region. In the following study, paper II, we propose a pathway by which IGF-1R is 
transported into the nucleus. IGF-1R is transported along microtubules via the dynactin 
transportation complex, to the nuclear pore where it is transferred to importin-β which guides the 
receptor to the nuclear pore complex protein RanBP2, which further assists the receptor into the 
cell nucleus in a RanGTPase dependent manner. Inhibition or obstruction of any of these 
components results in a reduction in nuclear IGF-1R. Further, we suggest that RanBP2 is the 
SUMO E3 ligase in IGF-1R SUMOylation and we show that SUMO-1 modification of the 
receptor is also important for its stability. In paper III, we demonstrate that the EGFR is 
SUMOylated and propose five lysine residues as SUMO-1 targets which were identified by two 
different mass spectrometry strategies. One of these residues, lysine 37, came up as a suggested 
target in both mass spectrometry methods. EGFR mutated in this site – EGFR-K37R – causes a 
decrease in protein levels as well as transcriptional activity of cyclin D1 and c-myc, two target 
genes of nuclear EGFR.  
 
To summarize, our data shows (I) a pathway by which nuclear IGF-1R is being transported and 
the functional importance of nuclear IGF-1R as a co-activator in transcription and (II) that the 
EGFR is also SUMOylated and might play a role in its transcriptional activity. Together these 
results may unravel new mechanisms for IGF-1R and EGFR that have implications in 
carcinogenesis.  
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1. INTRODUCTION 
 
1.1 CANCER 
 
Cancer, a word that most of the population is familiar with. A word charged with emotions. Even 
my nine year old nephews have heard of it and they describe it as ―a disease you can die from‖. 
According to ―Centers for Disease Control and Prevention‖, Atlanta ,USA, each year 12.7 million 
people worldwide will learn that they have cancer and out of those 60% will die from the disease 
[1]. Many of these deaths can be prevented and as we live longer the incidence of cancer is 
increasing. In Sweden the risk of getting cancer during your lifetime is 30%.  
 
1.1.1 Cellular imbalance 
 
Cancer is not just one disease. There are hundreds of different groups and subgroups of cancer 
and it can occur in all different tissues of the body. They all have one thing in common; cancer is 
when cells are growing out of control. In adults, normal cells are under strict control of a variety 
of different cellular mechanisms. The cells have a finite life span and in general they only divide 
and multiply to replace old cells or to repair an injury. When this fine balance between cellular 
life and death is disrupted the cell can keep on dividing and multiplying and give rise to cancer 
cells.  
 
Malignancy is caused by many different factors which can be dived into two sub-groups; 
inherited (genetic) or environmental origins. Inherited cancers are caused by germ-line mutations, 
whilst environmental factors give rise to somatic mutations, the latter one being more common.  
Examples of germ-line mutations are mutations in the BRCA1 and BRCA2 genes and the APC 
gene, which increase the risk for breast cancer and colon cancer respectively [2, 3]. Somatic 
mutations, on the other hand, arises from environmental factors such as ultraviolet exposure, 
tobacco, diet, alcohol and lack of physical activity, which is by far the more common cause for 
cancerogenesis [4].  
 
For a normal somatic (adult) cell to transform into a cancer cell it requires multiple mutations. A 
single mutation alone is not enough as our cells have many sophisticated back-up systems which 
act to prevent any abnormal cell to continue growing and dividing. Thus, a cell requires several 
mutations in either so-called oncogenes and/or tumor suppressors to drive malignant growth. 
Proteins encoded by oncogenes control cellular growth pathways and since their normal function 
is crucial for a cell’s survival it is highly evolutionary conserved. A protein becomes an oncogene 
when it starts promoting a disproportionate and uncontrolled growth signaling. This occurs 
through different mechanism; (I) point-mutations in the oncogene which can give rise to a 
consecutively active protein, (II) gene amplification of the DNA leading to the protein product 
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being overexpressed and (III) chromosomal translocation causing the oncogene to be under the 
control of a promoter causing excessive transcription. Whilst oncogenes are giving the cells ―a 
green light‖ for growth, tumor-suppressor genes act as the cells ―brakes‖. Many cancer cells have 
lost their ―brakes‖, i.e. loss-of-function in the tumor-suppressor genes which give rise to an 
oncogenic effect on the cells. Proteins encoded by tumor-suppressor genes can (I) control 
different stages of the cell cycle and can arrest the cell cycle at a specific step or inhibit cell 
proliferation, (II)  detect DNA damage during cell cycle check-points (III) promote apoptosis 
(cell death), and (IV) repair DNA damage. Many cancers have either deletions or point-mutations 
in the tumor-suppressor genes causing a loss of protein or non-functional protein [5].  
 
 
 
 
 
Figure 1. The different types of proteins that control cell proliferation. Aberrant or loss of function in any of these 
seven proteins; growth factors, growth factor receptors, intracellular transducers, transcription factors, DNA-repair 
proteins, cell-cycle control proteins and anti-apoptosis proteins can give rise to an oncogenic cell. 
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Even though the cellular genotype between cancer cells differs they all share the same phenotype 
which can be divided up into the following characteristics [6]: 
 
1. Sustaining proliferative signaling 
2. Evading growth suppressors 
3. Activating invasion and metastasis 
4. Enabling replicative immortality 
5. Inducing angiogenesis 
6. Resisting cell death 
7. Evading immune destruction 
8. Reprogramming of energy metabolism 
 
This thesis is mainly focusing on the first characteristic (Figure 1), which will be discussed in 
more detail in the following sections.  
 
1.1.2 Targeted cancer therapy 
 
This thesis studies basic molecular mechanisms in cancer biology. The long term aim, reaching 
beyond this thesis, is that our findings will help in the discovery of new drug targets and that it 
will eventually lead to more efficient and specific cancer drugs with fewer adverse side effects. 
 
Surgery, chemotherapy and radiation are the ―golden standards‖ for treating cancer and have 
been used for more than a hundred years [7, 8]. Traditional chemotherapy targets rapidly dividing 
cells, thereby affecting not only cancer cells but also, for example, cells in the intestine which 
leads to severe side effects.  Targeted therapies on the other hand, refer to a new generation of 
cancer drugs designed to target specific functions of cancer cells. Targeted therapies include two 
classifications of drugs; small-molecules and monoclonal antibodies [9]. Imatinib mesylate (also 
known as Gleevec) is a small-molecule kinase inhibitor that has shown to be a clinical success in 
both chronic myeloid leukemia and gastrointestinal stromal tumors [10-12].  Cetuximab and 
trastuzumab are two FDA approved monoclonal antibodies for treatments against metastatic 
colorectal cancer and HER-positive breast cancer respectively [13, 14]. These new classes of 
drugs have proven to be very efficient for certain subgroups of cancer, however, it has been 
shown that when treating cancer with a single target the risk for acquired drug resistance 
increases [15]. However, there are more studies emerging presenting very promising results using 
combined therapies; either targeted therapies in combination with radiation or chemotherapy or 
using multiple targeted therapies to avoid resistance and to get a better response [16, 17].   
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1.2 RECEPTOR TYROSINE KINASES (RTKs) 
 
Cell communication is controlled by molecular switches, i.e. proteins activate (or inactivate) 
other proteins which start a signaling cascade. Kinases are a group of enzymes that 
phosphorylates other proteins. A kinase transfers a phosphate group from adenosine triphosphate 
(ATP) to an amino acid of a protein substrate. The most common (and studied) amino acids that 
are phosphorylated at their hydroxyl group side chain are serine, threonine or tyrosine [18, 19].  
 
Tyrosine kinases are further dived into two subgroups; receptor tyrosine kinases (RTKs) and non-
receptor tyrosine kinases [20]. By sequencing the human genome 90 tyrosine kinase genes have 
been identified, and 58 of those are classified as RTKs, which are divided into 20 families, 
including receptors for insulin, epidermal growth factor (EGF), platelet-derived growth factor 
(PDGF) and vascular endothelial growth factor (VEGF). The remaining 38 non-receptor tyrosine 
kinases are grouped into 10 subfamilies and include, for example, Src, JAK and FAK [21]. Cell 
signaling through RTKs have been studied for decades and many essential signal transduction 
pathways have been identified. RTKs control cellular mechanisms such as proliferation and 
differentiation, metabolism, cell-cycle control and cell migration [22-24]. Via extracellular 
stimuli through RTK ligands, the cell transfers the signal through complicated signaling cascade 
pathways and in to nuclear events.  
 
Structurally, RTKs consist of three segments; the extracellular fragment which contains the 
ligand binding domain, a transmembrane helix and the cytoplasmic fragment that covers the 
tyrosine kinase catalytic activity [20]. The cytoplasmic portion is further divided up into a 
regulator juxtamembrane (JM) domain, the tyrosine kinase domain and the carboxy (c)-terminal 
region [22]. The extracellular fragment of the receptors contains a variety of different domains 
including immunoglobulin-like domains, fibronectin type III-like domains, leucine-rich domains, 
cysteine-rich domains and EGF-like domains. Based on the composition of the extracellular 
domain they are divided up into the 20 families (Figure 2) [20]. 
 
With the exception of the insulin receptor (IR) family, RTKs are monomeric but dimerizes upon 
ligand binding. (The structure of the IR family will be covered in section 1.3). When ligand binds 
to the receptor, the receptor goes through a conformational change into its active state, either as a 
dimer or as an oligomer [22]. Once activated, the receptor trans-autophosphorylates its dimeric 
partner [25, 26]. This creates binding sites for proteins containing Src homology 2 (SH2) domain 
and phosphotyrosine binding (PTB) domain [27, 28], which is the starting point of the signaling 
cascades (see section 1.5).  
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Figure 2. Schematic representation of the 20 subfamilies of human RTKs. Structural domains in the extracellular 
regions are marked according to the key. The intracellular domains are shown as red rectangles.  
Re-printed with permission from Elsevier [22]. 
 
Signal downregulation is controlled by receptor internalization (endocytosis) and protein tyrosine 
phosphatases (PTPs) [29, 30]. Internalized receptors are either targeted for degradation through 
the lysosome or the ubiquitin-directed proteasome or the receptors are re-cycled to the plasma 
membrane [30]. More than 100 PTPs genes have been identified and they function as enzymes 
which catalyze the de-phosphorylation and control the length and the duration of the response 
[31].  
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1.2.1 RTKs and cancer 
 
When trying to identify new drug targets to combat cancer cell growth there are certain criteria 
that should be met. Workman and Kaye summarized it as follows [32]: 
 
1. Frequency of genetic or epigenetic deregulation of the target or pathway in human cancer. 
2. Demonstration in a model system that the target contributes to the malignant phenotype. 
3. Evidence of the reversal of the malignant phenotype; for example by gene knockout. 
4. Practical feasibility, tractability or drugability of the target. 
5. Availability of a robust and efficient biological test to support the drug discovery 
program. 
6. Ability to run a robust cost-effective high-throughput screen. 
7. Availability of a structure-based drug design approach. 
 
Based on these criteria, RTKs are optimal drug targets and today there are drugs targeting ErbB-
2, EGFR, VEGFR. c-KIT, MET and PDGFR [33, 34]. 
  
In normal cells, RTK signaling is tightly regulated to keep cell growth under control. However, 
when this balance is perturbed and tyrosine kinase signaling is overexpressed, the cell starts to 
transform. Sequencing of the epidermal growth factor receptor (EGFR) revealed similarities with 
the oncogene v-ErbB [35]. This was one of the very first studies describing how cancer cells can 
be self-sufficient. Molecular dys-regulation of RTKs signaling, direct or in-direct, are causing 
cancer cells to be self-sufficient and are classified into three major groups; 
 
 Ligand independent signaling: Mutations of the EGFR has been found in cancers such as 
gliomas, non-small cell lung carcinomas (NSCLC) and ovarian carcinomas, with the type 
III deletion mutant, EGFRvIII, being the most common. EGFRvIII is missing the ligand 
binding domain and is constitutively phosphorylated and activates downstream signaling 
cascades [36]. 
 
 Mutations: As mentioned, there are truncated variants of RTKs which cause ligand 
independent signaling. There also are mutations of the downstream signaling proteins, 
thereby having an in-direct impact of RTK signaling. One such example includes 
inactivation mutation of the tumor suppressor PTEN (a phosphatase that inhibits AKT 
activation) [37]. 
 
 Autocrine signaling: A third way for cancer cells to obtain self-sufficiency is through 
autocrine signaling which is common in cancer cells. For example, IGF-1 is strongly 
expressed in melanoma cells and by inhibiting IGF-1 with antibody the IGF-1 receptor 
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(IGF-1R) is deactivated followed by MAPK signaling inactivation. This blocks the 
melanoma cell proliferation and causes a net loss of melanoma cells [38].   
 
1.3 THE INSULIN-LIKE GROWTH FACTOR (IGF) FAMILY  
 
The insulin-like growth factor (IGF) system regulates fundamental biological mechanisms 
throughout fetal and childhood development. In adult life, it regulates metabolism, proliferation, 
differentiation and apoptotic protection. The IGF family comprises of three ligands (IGF-1, IGF-
2 and insulin), three cell-surface receptors including the IGF-1R, the IGF-2R/mannose 6-
phosphate (M6P) receptor and the insulin receptor (IR) and six high affinity IGF-binding proteins 
(IGFBP-1 to 6) (Figure 3) [39].  
 
 
Figure 3. The IGF system with its ligands (insulin, IGF-1 and IGF-2), receptors (IR, IGF-1R, hybrid IR/IGF-1R and 
IGF-2R) and IGFBP1-6 with their proteases. Thick arrows and thin arrows indicate high and low ligand affinity 
binding. 
 
The IGF-2R is monomeric and structurally distinct from the IGF-1R and IR, e.g., it lacks the 
tyrosine kinase domain and as a consequence it does not belong to the tyrosine kinase family. It is 
a multi-functional protein and binds both IGF-2 and M6P [40]. However, the receptor lacks 
signaling capacity. It has two main functions; (I) regulating M6P-containing lysosomal enzymes 
by trafficking them between the trans-golgi network to lysosomes and (II)  regulating circulating 
IGF-2 by binding followed by internalization and lysosomal degradation [41, 42]. The receptors 
ability to regulate IGF-2 has proposed it to function as a tumor suppressor and IGF-2R mutations 
are found in human hepatocellular carcinomas [43]. 
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Insulin and the IR are generally regarded to regulate glucose metabolism and growth in normal 
tissue, but lately there is an increased focus on IR’s role in cancer progression [44]. The western 
lifestyle has led to increased occurrence in obesity and type 2 diabetes; two risk factors in 
malignant growth [45, 46]. The insulin receptor exists in two isoforms due to splicing of exon 11; 
IR-A and IR-B and it is the former isoform that has been suggested to play a role in 
cancerogenesis. IR-A, as opposed to IR-B, binds IGF-2 with high affinity. IR-A activation by 
insulin causes metabolic response, whilst IGF-2 dependent activation results mainly in mitogenic 
effects [47]. Overexpression of IR-A is reported in, for example, ovarian, hepatocellular and 
endometrial carcinoma [47-50]. Another emerging role of the IR-A in cancer progression is its 
ability to form a hybrid receptor together with IGF-1R [51, 52]. The hybrid receptor can be 
activated by IGF-1, IGF-2 and insulin [53]. 
 
1.3.1 Insulin-like growth factors 
 
IGF-1 and IGF-2 are extremely potent mitogens and play a pivotal role in regulating cell 
proliferation, differentiation and apoptosis. They exert their signaling through 
endocrine/paracrine as well as autocrine pathways.   
 
The IGF-1 is a 70 amino acid long peptide mainly produced by the liver in response to 
stimulation by growth hormone (GH). The structure of IGF-1 is 70% homologues to IGF-2 and 
50% homologues to pro-insulin [54]. After birth, the IGF-1 serum levels increase slowly and 
peak at puberty and then decline with age. In adults, serum levels of IGF-1 range between 100-
200 ng/ml [55]. Several studies propose that high serum levels of IGF-1 is a predictive factor in 
common cancers such as prostate, breast and colorectal cancers [56-59]. More recently, the link 
between IGF-1 and cancer was further established in an epidemiological study of 230 individuals 
with Laron syndrome, a form of dwarfism as a result of GH insensitivity, and as a consequence 
they suffer from IGF-1 deficiency. This study found that none of the 230 individuals worldwide 
developed cancer [60]. 
 
IGF-1 promotes cell division by stimulating cyclin D1 production and increasing DNA synthesis, 
which progresses the cell cycle from G1 to S phase [61, 62]. In addition to IGF-1’s mitogenic 
property it triggers an anti-apoptotic effect by increasing transcription of Bcl-xL protein and 
suppressing expression of Bax, which blocks the apoptotic pathway [63, 64]. 
 
The IGF-2 peptide consists of 67 amino acids and is produced by a variety of tissues. The IGF-2 
production is still not understood, but it is independent of GH [65]. The serum levels of IGF-2 are 
higher than the ones of IGF-1, ranging between 400-600 ng/ml. It is believed that IGF-2 is a key 
regulator during embryonic and fetal growth [55]. It is reported that in adrenal cortical malignant 
tumors the IGF-2 levels are up to 10 times higher in malignant tumors compared to benign or 
normal gland [66]. 
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1.3.2 Insulin-like growth factor binding proteins (IGFBPs) and proteases 
 
There are six IGFBPs that bind IGFs with high affinity. All six proteins share approximately 35% 
sequence identity. Less than 1% of IGFs are circulating in serum in free form. Most of the 
circulating IGFs exist as a ternary complex together with mainly IGFBP-3 but also IGFBP-5 and 
the glycoprotein acid labile subunit (ALS) [67]. 
 
IGFBPs bind IGFs and through three different mechanisms they affect the IGF stimuli in the 
body; (I) increase IGFs half-life from 10 minutes up to 12 hours (II) IGFBPs function as a 
transport receptor for IGFs and distribute them to extravascular spaces (III) regulate the 
interaction with IGF-1R [54]. IGFBPs either inhibit or enhance IGFs binding to the IGF-1R. 
Phosphorylation of IGFBP at the plasma membrane increases IGFs association with IGF-1R [68, 
69].  
 
There are several studies suggesting that some IGFBPs affect target cells through an IGF-
independent mechanism. IGFBP-3 has been reported to suppress tumor growth by blocking 
tumor angiogenesis [70] and it has been described to induce apoptosis independent of both p53 
and IGF-receptor mediated pathways [71]. 
 
IGFBPs binding to IGFs are further regulated by numerous different IGFBP proteases. Prostate-
specific antigen (PSA) is one serine protease that can cleave IGFBP-3 and IGFBP-5, making 
more IGF available to the cells [72, 73]. The complete regulation of IGFBP proteolysis is 
complex and not very well understood. 
 
1.3.3 Structure and activation of the IGF-1R  
 
The IGF-1R gene is located in chromosome 15 and contains 21 exons; exons 1-10 encoding the 
α-subunit of the receptor and the β-subunit is encoded by exons 11-21 [74, 75]. The IGF-1R is 
synthesized as a single-chain pro-receptor. With the assistance of chaperone proteins the pro-
receptor is glycosylated, folded and dimerized. In the Golgi the pro-receptor is cleaved in the 30 
amino acid signal peptide, containing the protease cleavage site, Arg-Lys-Arg-Arg,  generating 
the extracellular α-subunit (130-135 kDa) and the transmembrane/cytoplasmic β-subunit (90-97 
kDa) [74]. The subunits are linked with disulfide bonds between the α/β subunits and the α/α 
subunits in the mature α2β2 heterotetramer receptor (Figure 4) [76].  
 
Ligand binding of IGF-1 to the extracellular domain of the receptor triggers autophosphorylation 
of three tyrosine residues in the activation loop (a-loop); Tyr1131, Tyr1135 and Tyr1136 [77, 
78]. The autophosphorylation of the receptor stabilizes the a-loop in a conformation that 
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facilitates catalysis [79]. Following autophosphorylation, Tyr950 in the JM domain is 
phosphorylated and act as docking site for signaling molecules including insulin receptor 
substrates 1 (IRS-1) and Shc. Lysine 1003 in the tyrosine kinase domain corresponds to the ATP-
binding site [80, 81]. Mutations within the a-loop, Tyr950 or Lys1003 inhibit the IGF-1R’s 
mitogenic and transformation ability, demonstrating that these residues are required for both 
transformation and proliferation [82-85].  
 
The work presented in this thesis is a continuation of our group’s previous finding that the IGF-
1R is SUMOylated at three specific lysine residues, namely Lys1025, Lys1100 and Lys1120 and 
upon SUMOylation the receptor undergoes nuclear translocation [86]. 
 
The c-terminal tail of the receptor functions as a regulatory domain important in many IGF-1R 
signaling responses. Tyrosine residues 1250 and 1251 are together with histidine 1293 and lysine 
1294 important in the anti-apoptotic response [87]. Mutations of tyrosine 1250-1251 and serine 
residues 1280-1283 affect the cell proliferation and the IGF-1R’s transforming ability [88, 89]. It 
has also been proposed that phosphorylation of serine 1248 restrains the receptor’s kinase activity 
[90]. 
Figure 4. Schematic structure of IGF-1R with important domains and residues presented. S-S = disulfide bonds, Y = 
tyrosine, K = lysine. 
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1.3.4 IGF-1R as a target in cancer therapy 
 
In 1993, Sell et al., published a study showing that the IGF-1R is a pre-requisite for malignant 
growth. Mouse fibroblast embryo cells from the igf1r (-/-) knock-out, (R- cells), do not grow in 
serum free medium supplemented with platelet-derived growth factor, epidermal growth factor, 
and IGF-I, whilst the wild-type cells do. Further they provided evidence that R- cells grown in 
serum and stably transfected with the simian virus 40 (SV40) large T antigen or the Ha-ras, 
cannot be transformed [91, 92]. 
 
There are many clinical studies showing that most cancers overexpress IGF-1R [93, 94], but there 
are some exceptions, for example, a total loss of IGF-1R has been reported in prostate cancer 
bone marrow metastases [95] . Although IGF-1R’s role in cancer progression is undisputed, it is 
important to remember that it is not considered to be an oncogene per se. Activation of IGF-1R 
by IGF-1 is alone not sufficient for transformation, but after an oncogenic event has occurred it is 
well established that the IGF-1R plays a key role in cell survival, progression, apoptotic 
protection and DNA repair [96-98]. 
 
Recently, the IGF-1R expression has been postulated to function as a predictive and prognostic 
biomarker in different cancers. A few examples are listed below: 
 
 In a study consisting of 49 patients with surgically removed gastric cancer, of which 21 
patients had lymph node metastases, they found that IGF-1R expression associates with 
lymph node metastasis, it correlates with worse prognosis and is an independent predictor 
of survival in patients with gastric cancer [99]. 
 In metastatic colorectal cancer, high expression of IGF-1R correlates with longer 
progressive free survival (PFS) in combination with cetuximab treatment, thereby 
suggesting a predictive role of IGF-1R for patients that will benefit from cetuximab [100]. 
 IGF-1R is a strong predictive marker of lack of response to radiotherapy in patients with 
locally advanced HPV16-positive cervical cancer [101]. 
 Vilmer et al., showed in a study concluded of 33 patients with advanced NSCLC, that 
high IGF-1R mRNA expression correlates with shorter PFS compared to the negative 
subgroup; 6.1 months vs 7.4 months [102]. 
 
The IGF-1R’s expression in many different cancers and its ability to sustain tumor growth has 
made it an attractive pharmaceutical target. There are different techniques of targeting the IGF-
1R mediated signaling; antibodies or by small-molecule inhibitors. Other methods that have been 
discussed for IGF-1R downregulation are the use of dominant-negative receptors or RNA 
interference/antisense, but due to limitation in drug administration these are yet not a feasible 
option today [81].  
 
15 
 
However, results from clinical studies have been disappointing. Small-molecule inhibitors are 
very efficient in targeting the IGF-1R in vitro and in xenograft tumor models but there is a 
problem of IR cross-reactivity and toxicity but several compounds are still under investigation 
[103, 104]. Monoclonal antibodies are designed to target the extracellular domain of the IGF-1R, 
thereby inhibiting IGF-1 binding and receptor activation. The receptor is instead internalized and 
downregulated. The effects of tumor regression is very prominent in vitro and the tolerance 
against antibodies in the human body are in general good [104]. However, it seems like it is only 
a subset of patients that benefit from antibody therapy and there is also a problem with patients 
developing resistance against the drug [105]. 
 
Proposed explanations to the discouraging results in the clinical trials with IGF-1R targeted drugs 
include (I) targeting IGF-1R with antibody in tumor lacking IRS-1 is inefficient [106]. Without 
IRS-1, IGF-1R signals differentiation response rather than a mitogenic response (II) Resistance 
through switching from IGF-1R dependency to EGFR dependency (and vice versa) [82, 107] (III) 
Resistance due to tumor heterogeneity, there are evidence of subpopulations of cancer cells in 
human tumors [108] (IV) Failure to target IGF-1R might also be as a consequence of mutations 
in the PI3K pathway making it constitutive  active independently of IGF-1R activation [109] and 
(V) the presence of nuclear IGF-1R (which will be reviewed in section 1.8). 
 
However, IGF-1R might still be a very useful target to combat cancer, but it might be more 
efficient and give better response in combination therapies rather than as a single agent.  
 
1.4 THE ERBB FAMILY 
 
The ErbB tyrosine kinase receptor family consists of four receptors. Stanley Cohen was the first 
researcher who described the epidermal growth factor receptor (EGFR), which is also referred to 
as ErbB-1/HER-1. Cohen identified the EGF, EGFR and its tyrosine kinase activity. The other 
three member consist of ErbB-2 (HER-2/Neu), ErbB-3, (HER-3) and ErbB-4 (HER-4). The ErbB 
name is derived for the avian erythroblastosis oncogene, which the human receptors are 
homologous to. The v-ErbB oncoprotein lacks the EGF ligand binding domain; mimicking 
activated EGFR, resulting in a constant growth signal to the cell.[110].  
 
The four receptors, together with 13 polypeptide ligands, containing a conserved EGF domain, 
make up a complex signaling network (table 1) [111]. Receptor activation of the ErbB family 
includes both homo- and heterodimers. ErbB-2 lacks the ligand binding domain and to function it 
has to form a heterodimer with EGFR, ErbB-3 or ErbB-4. The ErbB-3 also relies on the other 
receptors since it has a defective tyrosine kinase domain [112, 113], although a recent study 
suggests that the ErbB-3 has some phosphorylation activity [114]. 
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Table 1. Specificity of ErbB receptors and ligands. Re-printed with permission from Elsevier [111]. 
Ligand Receptor 
  ErbB-1 ErbB-2 ErbB-3 ErbB-4 
EGF + − − − 
TGF-α + − − − 
HB-EGF + − − + 
Amphiregulin + − − − 
Betacellulin + − − + 
Epigen + − − − 
Epiregulin + − − + 
Neuregulin-1 − − + + 
Neuregulin-2 − − + + 
Neuregulin-3 − − − + 
Neuregulin-4 − − − + 
 
The ErbB signaling network is involved in numerous different biological processes. Null 
mutations of any of the ErbB genes are lethal – embryonic or perinatal –  with defects in  heart, 
skin, lung, gastrointestinal tract, brain and kidney [110]. Insufficient ErbB signaling through the 
ligand neuregulin-1 is found in neurodegenerative diseases such as Parkinson disease, 
schizophrenia and multiple sclerosis [115, 116], whilst overabundant signaling (due to receptor 
overexpression, mutations or autocrine signaling) is well documented in many different 
carcinomas [110, 117].  
 
The ErbB network is very complex, and for the purpose and aim of this thesis I will now focus on 
the EGFR.  
 
1.4.1 EGFR structure 
 
The extracellular domain of the EGFR consists of two ligand binding domains (domains I and III) 
and two cysteine rich domains (domains II and IV) [20]. The activated receptor is 
autophosphorylated at six tyrosine residues in the c-terminal tail; Tyr1068, Tyr1148 and Tyr1173 
are the major sites [118] and Tyr992[119], Tyr1045[120] and Tyr1086[121] are minor 
autophosphorylation sites. The kinase domain of EGFR is divided into two parts; the N-lobe and 
the C-lobe, and upon activation two monomeric receptors will dimerize asymmetrical, connecting 
the N-lobe of one receptor to the C-lobe of the other (Figure 5) [122]. Ligand activation of EGFR 
initiates signaling cascades of the ras/raf/MEK/MAPK pathway and the PI3K pathway.  
 
17 
 
 
Figure 5. Schematic structure of EGFR with important domains and residues presented. 
 
1.4.2 EGFR in cancer therapy 
 
Several in vitro studies have shown that overexpression of EGFR induces transformation together 
with ligand [123, 124]. Today EGFR overexpression is established in many different cancers; 
lung cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, pancreatic 
cancer and glioblastoma. Overexpression of the EGFR is most commonly a result of gene 
amplification [125]. Other genetic variations of the EGFR in carcinoma are summarized in Table 
2.  
 
In a study containing 31 colorectal cancer patients, they identified that eight out of nine patients 
who responded to anti-EGFR treatment (cetuximab or panitumumab) had an increased EGFR 
gene copy number and that there is no correlation with mutations occurring in the EGFR catalytic 
domain (exons 18-21). This suggests that EGFR gene amplification is a good way to select 
patients which benefits from anti-EGFR treatment [126].  
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Table 2. Genetic alterations of the EGFR in human carcinoma. Re-printed with permission from Elsevier [125]. 
Genetic alteration in EGFR 
Ligand 
dependence 
Gene amplification + 
N-terminal truncation (EGFRvI) − 
Deletion exons 14–15 (EGFRvII) + 
Deletion exons 2–7 (EGFRvIII)  
Deletion exons 25–27 (EGFRvIV) + 
C-terminal truncation (EGFRvV) + 
Tandem duplication exons 2–7 + 
Tandem duplication exons 18–25 − 
Tandem duplication exons 18–26 − 
Small in frame deletion or point mutations in the kinase domain (exons 18–21) + 
 
Today there are six drugs approved by the FDA targeting the EGFR. Four of them which are 
small-molecule inhibitors targeting the receptor [110]: 
 
 Afatinib: First-line treatment of NSCLC if patients have exon 19 or the exon 21 L858R 
mutation. Approved 2013. 
 Erlotinib: First-line treatment with the same indications as afatinib or as a second-line 
treatment following chemotherapy or as a first-line treatment of pancreatic cancer in 
combination with gemcitabine. Approved 2004. 
 Gefitinib: Second-line treatment of NSCLC after chemotherapy. Approved in 2005, but 
withdrawn in the United States due to lack of evidence that it prolonged survival, but still 
used in many different countries [127].  
 Lapatinib: A dual inhibitor, which also targets ErbB-2. Second-line treatment in ErbB2-
positive breast cancer in combination with chemotherapy or with letrozole in post-
menopausal hormone receptor-positive breast cancer. Approved 2007. 
 
Approved antibodies include the chimeric cetuximab and the human antibody panitumumab: 
 
 Cetuximab: to be used in wild-type KRAS colorectal cancer in combination with 
chemotherapy or in head and neck cancers in combination with chemotherapy/radiation. 
Approved 2004. 
 Panitumumab: Second-line treatment for metastatic colorectal cancer after cytotoxic 
therapies. Approved 2006.  
 
Targeted therapies are still relatively new on the market and several ongoing clinical studies are 
evaluating new substances and the above mentioned molecules/antibodies to get their approval 
extended for other cancers or to be used in combination therapies.  
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1.5 SIGNALING PATHWAYS  
 
As I have already mentioned, upon ligand binding of RTKs they become activated and send their 
survival, proliferation and anti-apoptotic signals through cytoplasmic signaling cascades. These 
signaling pathways are very important in understanding the tumorigenic effect RTKs have in 
cancer cells. My projects presented in this thesis do not cover these pathway as such, but I will 
here, very simplified and schematically cover the two major pathways activated by both the IGF-
1R and the EGFR; the PI3K and MAPK pathways. I will focus on the IGF-1R line of activation, 
however in principal it works the same for EGFR activation, but at certain stages there are 
different adapter/scaffolding proteins or EGFR-specific substrates involved. 
 
1.5.1 The PI3K/Akt pathway  
 
The phosphatidylinositol 3-kinase (PI3K) pathway is involved in cell survival, proliferation, 
protein translation and glucose metabolism. Upon IGF-1R activation and phosphorylation of 
tyrosine 950, insulin receptor substrate proteins (IRS 1-4) binds to the receptor [80]. 
Phosphorylated IRS-1 at tyrosine residues 612 and 632 recruits the p85 regulatory subunit, 
followed by activation of the catalytic domain of the PI3 kinase, p110 [128]. Activation of PI3K 
results in an increase in phosphatidylinositol 3,4,5-triphosphate (PIP3) from phosphatidylinositol 
3,4-triphosphate (PIP2) and recruitment of the serine/threonine Akt kinase. The constitutively 
activated 3´-phosphoinositide-dependent kinases (PDK1 and 2) phosphorylate Akt at threonine 
308 and serine 473 [129, 130]. 
 
Activated Akt is an important step in the PI3K signaling cascade; once it is phosphorylated it 
affects downstream signaling in a complex network. Akt inhibits apoptosis through 
phosphorylation of for example: (I) forkhead related transcription factors, such as FoxO. 
Phosphorylation inhibits FoxO’s nuclear translocation and thereby its transcriptional activity of 
pro-apoptotic proteins such as Fas Ligand and Trail [131] (II) the Bcl-2 family member BAD and 
caspase 9, thereby suppressing apoptosis and promoting cell survival [132, 133] (III) the pro-
apoptotic GSK-3β and (IV) Mdm2, which translocates into the nucleus and suppresses 
transcription of the tumor suppressor gene p53 and increase p53 degradation [134, 135]. 
 
Further, Akt activates proteins like mammalian target of rapamycin (mTOR) and NF-κβ. The 
mTOR kinase regulates protein synthesis and is thereby a major effector of cell growth and 
proliferation. Two downstream targets of mTOR are 4E-binding protein 1 (4E-BP1) and S6 
kinase (S6K1) [136]. Phosphorylation of 4E-BP1, which is a repressor of translation, leads to its 
inhibition, thereby increasing protein translation of e.g. c-myc and cyclin D1, two proteins 
important in cell-cycle progression [23]. S6K1, a ribosomal protein, is activated upon mTOR 
phosphorylation and increase protein synthesis [137]. 
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One of the effectors responsible for inactivation of the PI3K/Akt pathway is phosphatase and 
tensin homologue (PTEN). It negatively regulates PIP3 levels, causing PI3K/Akt inhibition. 
PTEN acts as a tumor suppressor and PTEN deletion is found in  40  of all prostate cancers 
[138] and more than 330 somatic PTEN mutations have been reported in primary tumors and 
metastasis [139]. As a result of deletion or loss of function of PTEN, RTK signaling through 
PI3K is strengthened. Schematic overview of PI3K/Akt signaling pathway is shown in Figure 6.  
 
1.5.2 The MAPK pathway 
 
The second major signaling pathway for the IGF-1R and EGFR is the mitogen-activated protein 
kinase (MAPK) pathway (also known as the extra-cellular signal-regulated kinase (ERK) 
pathway.) Tyrosine 950 of the IGF-1R also functions as a docking site for Shc adapter proteins 
[39, 140]. Grb2 is a small protein containing one SH2 domain and two SH3 domains and can 
interact with both IRS-1 and Shc via the SH2 domain [141]. Through the N-terminal SH3 domain 
Grb2 interacts with son of sevenless (SOS) as a preexisting complex in the cytosol. The 
recruitment of Grb2/SOS to Shc or IRS-1 makes it available for binding to the membrane 
associated GTPase Ras. Upon activation, Ras exchanges GDP for GTP and activates Raf [142], 
which is a key point in the cascade signaling. Raf activates MEK1/2 (MAP kinase kinase), which 
in turn activates ERK1/2 (MAP kinase) through phosphorylation and results in a cellular response 
that triggers cell proliferation and survival (Figure 6) [143, 144].  
 
Activated ERKs translocate into the cell nucleus and phosphorylate transcription factors such as 
Elk1, Ets1 and Ets2, c-Myc, STAT-3 and Sp1 [145-149]. This results in an activation of 
transcription through recruitment of co-factors, or they promote transcription by relieving 
repressive mechanism, for example, activation of ERKs result in removal of small ubiquitin-like 
modifier (SUMO) from a second regulatory domain of Elk-1, allowing activation of transcription 
by Elk-1 [150]. 
 
There are substantial evidence of the importance of the MAPK/ERK signaling pathway in cancer 
progression, cell growth and metastasis. For example, constitutively activated mutants of Raf and 
MEK transform rodent fibroblasts [144] and B-Raf is commonly mutated in malignant melanoma 
[151]. Today many different inhibitors against Ras/Raf/MEK are under clinical investigations. 
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Figure 6. Schematic simplification of MAPK and PI3K signaling upon IGF-1R activation. 
 
1.5.3 The Wnt/β-catenin signaling pathway  
 
In the first project presented in the results section, we investigated IGF-1R’s role as a potential 
co-activator of LEF1/TCF (lymphoid enhancing factor/T-cell factor) transcription factor. 
Therefore, I am introducing the Wnt/β-catenin signaling pathway.  
 
The Wnt/β-catenin signaling is an evolutionary conserved pathway. Wnt was first discovered as 
segment polarity gene in Drosophila melanogaster, where its function is important in the 
formation of the body axis during embryonic development, and due to the knockout phenotype it 
was given the name wingless (Wg). Later the  name was fused with the vertebrate homolog, 
integrated or Int-1 giving rise to new name Wnt (wingless-related integration site) [152]. 
 
There are several intra-cellular pathways stimulated by Wnt. The three main pathways are; the 
canonical Wnt/β-catenin pathway, the non-canonical planar cell polarity pathway and the non-
canonical Wnt/calcium pathway [153]. Here I only present the canonical pathway which includes 
β-catenin. 
 
In humans, 19 Wnt genes are identified and the genes are predicted to encode secreted proteins 
[154]. Wnt proteins are glycoproteins that bind to the extracellular domain of the Frizzled (Fz) 
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receptor family. The Fz receptors share homology with G-protein couple receptors and are  
seven-pass transmembrane proteins [155]. When there is no ligand bound to the receptor, 
cytoplasmic β-catenin is degraded by a protein complex consisting of Axin, adenomatosis 
polyposis coli (APC) and glycogen synthase kinase 3 (GSK3). Casein kinase 1α (CK1) 
phosphorylates β-catenin within this complex followed by ubiquitination by β-Trcp, thereby 
targeting β-catenin for degradation by the proteasome [156]. Wnt and the Fz receptor require 
interaction with a co-receptor to become fully activated, namely with the low density lipoprotein-
related protein 5/6 (LRP5 and LRP6) [157]. Once the two receptors are activated through Wnt 
binding, the cytoplasmic phosphoprotein Dishevelled (Dsh) directly interacts with Fz followed by 
Axin translocation to the LRP receptor. This results in accumulation of β-catenin, followed by its 
nuclear translocation [153, 157, 158]. Nuclear β-catenin forms an active transcriptional complex 
with LEF1/TCF by displacing the transcriptional inhibitor Groucho and CBP [159, 160] (Figure 
7). Target genes of β-catenin/LEF1/TCF transcription complex include C-MYC [161], AXIN2 
[162] and cyclin D1 [163]. 
 
 
Figure 7. Wnt signaling pathway. (a) In the absence of active Wnt β-catenin is degraded. (b) Activated Wnt 
signaling causes β-catenin accumulation and its nuclear translocation. It induces transcription through binding to 
LEF1/TCF transcription factors. Re-printed with permission from Nature Publishing Group [164] 
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The Wnt/β-catenin transduction pathway is important for embryonic development [155, 165, 
166] and is crucial for angiogenesis in the central nervous system [167]. Aberrant signaling 
associates with many different human diseases. A single amino acid substitution mutation in 
LRP5 causes an increase in bone density in e.g the jaw [168], whilst another LRP5 mutation 
instead causes a loss-of function and results in the autosomal recessive disorder osteoporosis-
pseudoglioma syndrome and a decrease in bone mass [169]. Hyperactivation in the Wnt/β-catenin 
signaling pathway (as a result of mutations) is important in carcinogenesis. For example, 
truncations in APC result in Wnt activation, which increases cell proliferation and leads to 
adenomatous lesions. This give rise to familial adenomatous polyposis, an autosomal, dominantly 
inherited disease in which patients display hundreds or thousands of polyps in the colon and 
rectum [170, 171].  
 
The Wnt/β-catenin pathway has extensive crosstalk with RTKs, including both IGF-1R and 
EGFR signaling. Aberrant Wnt signaling associates with an increased risk of type 2 diabetes 
[172-174]. Palsgaard et al., found that Wnt stimulation leads to phosphorylation of Akt, GSK3β, 
and ERK1/2 and that it is insulin/IGF-1 receptor dependent. LRP5 interacts with the insulin 
receptor and knockdown of LRP strongly decreases insulin induced phosphorylation of 
downstream mediators [175]. IGF stimulation results in phosphorylation of β-catenin, followed 
by disassociation from E-cadherin, a protein important in cell-cell adhesion [176, 177]. 
Disruption between β-catenin and E-cadherin is important in the initiation of epithelial-
mesenchymal transition [176, 178]. IGF stimulation leads to a rapid nuclear translocation of β-
catenin followed by an increase in transcription [177, 179]. Collectively, these studies add 
another multiplex level in understanding the IGF signaling. 
 
1.6 SMALL UBIQUITIN-LIKE MODIFIER (SUMO)  
 
The IGF-1R was the first RTK revealed to be SUMO modified. Since then it has also been 
demonstrated that the IR and the intra-cellular domain of ErbB-4 are SUMOylated [180, 181]. 
 
Phosphorylation and ubiquitin are two post-translational modifications that have been mentioned 
above and they rapidly send biological messages across the cell. A third post-translational 
modification that is being studied more and more is small ubiquitin-like modifier, SUMO. One 
reason to why this modification was discovered relatively late could be that there is only a small 
portion of substrate modified at any given time, usually around 1% [182]. It was originally found 
to modify proteins within the cell nucleus, but as more research has been carried out it has also 
been found to regulate mechanisms within other compartments of the cell.  
 
SUMO proteins (also known under names such as Smt3p[183], PIC-1[184], GMP1[185], and 
sentrin [186]),  have a mass of   11 kDa and approximately 100 amino acids. SUMOs are highly 
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conserved within eukaryotes and expressed in all tissues and cells and are essential for cell 
viability [187] There are four SUMOs identified in mammals; SUMO-1, SUMO-2, SUMO-3 and 
SUMO-4.  
 
SUMO-1 and ubiquitin share 18% amino acid sequence identity, but their 3D structures are 
closely related. However, their charge topology differs significantly suggesting the two proteins 
have different target substrates and modifying enzymes [188]. SUMO-2 and SUMO-3 share 97% 
identity with each other and are often referred to as SUMO-2/3. They only share 50% with 
SUMO-1 but 86% identity with SUMO-4 [189]. It has been suggested that SUMO-4 lacks the 
ability to form covalent isopeptide bonds with substrates [190]. 
 
There are a few differences observed between SUMO-1 and SUMO-2/3. Saitoh et al. showed that 
there are high amounts of unconjugated SUMO-2/3 in cells, whilst most SUMO-1 are conjugated. 
When exposing the cells to stress through acute temperature changes, the amount of conjugated 
SUMO-2/3 to high molecular mass proteins rapidly increase, whereas no change is observed in 
the amount SUMO-1 conjugated proteins [191]. Some proteins, like RanGAP1, are preferentially 
SUMOylated by SUMO-1 [191] and other proteins, like the human thymine-DNA glycosylase, is 
modified equally well by SUMO-1 and SUMO-2/3 [192]. Another difference between the two 
SUMO groups is that SUMO-2/3 contains an internal consensus site for SUMOylation in their N-
terminal allowing SUMO chain formations [193]. Poly-SUMO chains are identified for 
proliferation-cell nuclear antigen (PCNA) [194],  promyelocytic leukima protein (PML) [195] 
and histone deacetylase 4 (HDAC4) [193]. 
 
The SUMO consensus site is described as ΨKXE, where Ψ is a large hydrophobic amino acid; K 
is the modified lysine residue; X is any residue; and E is a glutamic acid. This sequence is very 
short and exists in many proteins, and it is unlikely that all those sites are SUMOylated [187]. 
Many SUMOylated proteins are indeed SUMO modified at different sites [196-199], for 
example, the three SUMO-1 sites identified in the IGF-1R do not have this consensus sequence 
[86]. 
 
1.6.1 SUMOylation ligases 
 
The process of SUMO attaching to a target protein is referred to as SUMOylation and is 
homologous to the mechanism of ubiquitylation. It involves three enzymatic steps; activation, 
conjugation, and ligation (Figure 8); 
 
 SUMO-activating enzyme (E1): This is an ATP dependent step, which results in a high-
energy thioester bond between the E1 and a glycine residue in the c-terminal of SUMO. 
This step is achieved by the heterodimeric SUMO activating enzyme 1 and 2 
(SAE1/SAE2), also known as Aos1/Uba2 [200].  
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 SUMO-conjugating enzyme (E2): After activation, SUMO is transferred to a cysteine 
residue on the E2 enzyme. Unlike the ubiquitin pathway, there is only one E2 enzyme 
known for SUMOylation; Ubc9 [201, 202]. SUMO and Ubc9 form a thioester 
intermediate through a conserved catalytic cysteine residue of Ubc9 and the c-terminal of 
SUMO [200]. 
 
 SUMO ligases (E3): In the last step, SUMO is transferred from Ubc9 to the substrate with 
the aid of an E3 ligase, which mainly serves to increase stability of the SUMO 
conjugation. An isopeptide bond forms between the glycine residue of SUMO and the 
target lysine residue of the substrate [203].  
 
 
Figure 8. Schematic representation of the SUMOylation pathway. Mature SUMO is activated by SAE1/SAE2 in an 
ATP dependent manner. Subsequently, SUMO is transferred to the E2 conjugation enzyme Ubc9 and finally 
conjugated to the substrate by an E3 ligase. SUMO conjugation can be reversed by protease activity of SENPs 
thereby releasing free SUMO. 
 
There are three distinct groups of SUMO E3 ligases [187, 203, 204]; (I) Members of the PIAS 
(protein inhibitor of activated STAT) family. Six mammalian PIAS proteins are identified; 
PIAS1, PIAS3, KChaP (splice variant of PIAS3), PIASxα, PIASxβ and PIASγ. PIAS proteins 
contain a SP-RING domain which binds directly to Ubc9 and essential for the SUMO E3-ligase 
activity [205, 206]. (II) The polycomb protein Pc2, which is a part of the large multimeric 
complex polycomb group (PcG). By recruiting Ubc9 and CtBP (c-terminal binding protein) to 
PcG bodies, CtBP will be SUMOylated [207] and (III) the Ran binding protein 2, RanBP2. This 
large protein is located at the cytoplasmic fibril of the nuclear pore complex and it is believed to 
SUMOylate certain proteins upon nuclear translocation. It SUMOylates RanGAP, and in the case 
of RanGAP it forms a stable trimeric complex between SUMO-RanGAP and Ubc9 [208]. 
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1.6.2 SUMO-specific proteases (SENPs) 
 
There are two main functions of SUMO-specific proteases; to mature newly synthesized SUMO 
by cleavage in the C-terminal tail and to make the SUMOylation reversible by removing SUMO 
from substrates. These enzymes are called ubiquitin-like proteases in yeast and sentrin-specific 
proteases (SENPs) in mammals [209]. Even though the SUMOylation process is very similar to 
the ubiquitylation, there are few similarities between SENPs and DUBs (de-ubiquitinating 
enzymes). SENPs appear to be more structural related to viral proteases [210]. Another difference 
is that there are >100 DUBs identified, but only seven SENPs; SENPs 1-3 and 5-7 [211].  
 
Due to the low number of SENPs it is believed that the specificity of the SENPs is regulated by 
their sub-cellular localization. For example, SENP1 is mainly localized in the nucleus and is 
essential in mouse embryos for deSUMOylation of SUMO-1 [212, 213]. SENP2 binds RanBP2 
in the nuclear pore and processes SUMO-2 more efficiently than SUMO-1 and SUMO-3 [214]. 
Further, SENP7 localizes in the nucleoplasm and functions as a SUMO-2/3 protease rather than 
SUMO-1 and it only regulates substrate cleavage and is unable to process SUMO pre-cursors 
[215].  
 
1.6.3 SUMO targets and biological function 
 
The biological functions of SUMOylated proteins described in the literature include facilitating 
nuclear translocation, DNA repair, suppress or activate transcription and stabilizing multi-protein 
complexes [187, 200].  
 
There are several studies showing that SUMOylation affects subcellular trafficking of the target 
protein. In the case of the transcription factor Elk-1, it has been demonstrated that upon 
SUMOylation, Elk-1 translocates from the nucleus to the cytoplasm and thereby inhibits 
transcription [216]. Kishi et al. have described a similar event for SUMOylated Pdx1, but in 
reverse, i.e. the transcription factor Pdx1 will upon SUMO-1 modification translocate into the 
cell nucleus and activate transcription of the insulin gene [217]. The tumor suppressor p53 is 
another example where gene activation is enhanced upon SUMOylation [218].  
 
SUMOylation of thymine-DNA glycosylase (TDG) plays a crucial role in the DNA repair. TDG 
initiates base excision repair, where uracil/thymine mismatches to guanine are repaired. Once the 
damage is repaired TDG needs to be SUMOylated in order to disassociate from the so called 
harmful abasic site [192]. SUMO modification plays an important role in PML nuclear bodies, 
where SUMOylation of PML links and stabilizes this heterogenetic group of proteins [187, 219]. 
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1.7 CYTOPLASMIC-NUCLEAR SHUTTLING  
  
The nuclear envelope, which separates the cytoplasm from the nucleoplasm, is a double 
membrane structure. In order to pass signals from the cytoplasm into the cell nucleus or for 
synthesized RNA molecules to leave the nucleus they have to pass this barrier, and they do so 
through the nuclear pore complexes (NPCs). Smaller molecules, such as water and nucleotides, 
are able to passively diffuse through the NPCs, whereas larger molecules, >40 kDa require active 
transportation [220]. 
 
1.7.1 The nuclear pore complex (NPC)  
 
The NPC is one of the largest and most complex multi-protein assemblies in the eukaryotic cell. 
The NPCs make up aqueous channels which transport molecules from the cytoplasm into the 
nucleus and vice versa. The complex contains approximately 30 different evolutionary conserved 
proteins, referred to as nucleoporins (Nups) and each protein exists in multiple copies. In total, 
this multifaceted unit includes 500 – 1000 protein molecules [221].  By using electron 
microscopy the size of the NPC is   150 nm long and 60-70 nm wide at the cytoplasmic and 
nuclear periphery and 45 nm wide in the central part of the complex [222].  
 
The NPC structure is divided into different parts; cytoplasmic filaments, central channel, spoke 
complex, lumenal ring, cytoplasmic and nucleoplasmic rings and a nuclear basket (Figure 9) 
[223]. The cytoplasmic filaments consist of phenylalanine-glycine (FG) repeats that interact with 
transport receptor and are composed by the largest nucleoporin, RanBP2 (also known as Nup358) 
[224]. The ―FG Nups‖ have shown to function as direct mediators in cytoplasmic-nuclear 
shuttling by serving as docking sites for transport receptors [225, 226].  
 
 
 
Figure 9. Schematic representation of the major structures in the nuclear pore complex. Re-printed with permission 
from Nature Publishing Group [223].  
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1.7.2 Transport through the NPC  
 
Active transportation through the NPC requires several timely coordinated protein interactions.  
Transport receptors in humans are proteins belonging to the karyopherin family. Today there are 
more than 20 karyopherins identified in humans and they are subdivided into two groups: 
karyopherin α and karyopherin β [227]. Karyopherins involved in importing proteins to the 
nucleus are also known as importins and export karyopherins are known as exportins. From this 
point forward I will use this terminology. 
 
Importins recognize proteins targeted for nuclear translocation by a nuclear localization signal 
(NLS). Importin-α was the first identified importin to be able to bind to a NLS. Importin-β forms 
a heterodimer with importin-α, but it has been demonstrated that importin-β can direct nuclear 
translocation without binding to the α-subunit [228-230]. The structure of importin-α is 
composed of ten armadillo (ARM) repeats, repetitive amino acid sequence of   40 amino acids 
which forms three α-helices, and these ARM repeats recognize the NLS of cargo proteins [231]. 
Importin-β contains a similar repetitively structure named HEAT, which forms a superhelical 
coil. These repeats are flexible structures allowing recognition of many different cargos [227]. It 
is worth mentioning that it has been reported that proteins can undergo nuclear translocation 
without the aid of importins, e.g., β-catenin can associate – independently of transport receptors – 
with Nups followed by nuclear translocation [232].  
 
There are different types of NLS sequences identified and they are classified as ―classical NLS‖ 
or ―non-classical NLS.‖ Examples of classical NLSs include the monopartite sequences 
PKKKRKV (found in the SV40 T antigen) and PAAKRVKLD (found in c-myc) and the bipartite 
sequence VKRPAATKKAGQAKKKKLD (found in nucleoplasmin) [231]. The classical NLSs 
contain either one or two clusters of basic residues. Further, by screening of peptide libraries 
against binding to importin-α, Kosugi et al. proposed six classes of NLS sequences with 
consensus motives (Table 3) [233]. In contrast, the non-classisical NLS sequence M9 (found in 
hnRNP) contains acidic amino acids [234, 235].  
 
The core of the cytoplasmic-nuclear trafficking of molecules involves the RanGTPase system. 
Ran is a small GTPase of the Ras superfamily and it is essential for nuclear translocation. The 
Ran transportation cycle also includes Ran guanine nucleotide exchange factor (RanGEF) and 
Ran GTPase activating protein (RanGAP). On the cytoplasmic side, Ran is bound to RanGDP. 
Substrate bound to importin-α/β translocates into the nucleus through binding to RanBP1/2. 
Inside the nucleus RanGAP converts GDP to GTP, and RanGTP will bind to the importin/cargo 
complex, resulting in cargo release into the nucleus. RanGTP-importin complex shuttles back to 
the cytoplasmic side where RanGEF hydrolysis RanGTP and making importin available for a 
new transportation cycle. The cellular localization of RanGEF (cytoplasm) and RanGAP 
(nucleus) creates a concentration gradient of RanGDP and RanGTP making this shuttling 
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possible. A small RanGDP-binding protein, nuclear transport factor 2 (NTF2) contributes to 
maintaining this gradient by facilitating RanGDP import into the nucleus [236].  
 
Table 3. Six classes of NLS sequences proposed by Kosugi et al. [233]. Sequence representation is as follows: 
(^DE), any amino acid except Asp or Glu; X10–12, any 10–12 amino acids. Re-printed with permission from the 
American Society for Biochemistry and Molecular Biology. 
NLS class Consensus sequence 
Class 1 KR(K/R)R, K(K/R)RK 
Class 2 (P/R)XXKR(^DE)(K/R) 
Class 3 KRX(W/F/Y)XXAF 
Class 4 (R/P)XXKR(K/R)(^DE) 
Class 5 LGKR(K/R)(W/F/Y) 
Bipartite KRX10–12K(KR)(KR) 
Bipartite KRX10–12K(KR)X(K/R) 
 
1.8 NUCLEAR RTKs  
 
In previous sections the traditional RTK signaling has been covered, i.e. ligand binding induces 
dimerization, followed by autophosphorylation allowing adaptor proteins to attach and activate 
the downstream signaling cascade. Even though it still might be considered somewhat 
controversial, there is more and more evidence emerging of a non-canonical RTK signaling 
pathway, namely the topic of this thesis; their ability to translocate into the cell nucleus. Today 
several RTKs have been reported to localize in the cell nucleus, e.g the ErbB receptor family 
[237-241], FGFR [242], IGF-1R [86], InR [243], Ryk [244], TrkA [245] and VEGFR2 [246].  
 
1.8.1 Mechanisms for nuclear translocation 
 
There have been different investigations and hypothesis presented trying to explain the 
mechanisms behind RTKs nuclear translocation. There are several studies demonstrating that 
RTKs undergo proteolytic cleavage creating a soluble intra-cellular domain (ICD) which 
translocates to the nucleus. Within the category of cleaved receptor, ErbB-4 is the most studied. 
ErbB-4 has several isoforms as a result of alternative splicing, two of these are the 
juxtamembrane isoforms JMa and JMb. Ligand stimulation of ErbB-4-JMa results in cleavage in 
the extracellular juxtamembrane region; resulting in a 80 kDa membrane-bound intra-cellular 
fragment, which is further processed by a γ-secretase complex, releasing a soluble ICD [247]. 
This ErbB-4-ICD fragment contains a NLS sequence that further mediates its import to the 
nucleus [248]. Other RTK fragments found in the nucleus due to splice variants include e.g., 
EGFR and ErbB-3 [249, 250]. 
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However, the most controversial issue regarding nuclear RTKs is the discovery of intact 
receptors, holoreceptors, inside the nucleus. Seemingly, the biggest obstacle is how a membrane-
bound receptor can translocate into the cell nucleus. Holoreceptors identified in the nucleus 
include EGFR, ErbB-2, ErbB-4, IGF-1R, and FGFR amongst others.   
 
Nuclear translocations of the EGFR and ErbB-2 occur through a retrograde transportation [251-
253]. Wang et al. suggested two alternative routes for the nuclear transport of RTKs [252];  
 
1. The INTERNET pathway; integral trafficking from the ER to the nuclear envelope 
transportation. This pathway involves ligand-induce internalization of the receptor which 
translocates to Golgi, followed by retrograde transportation to the endoplasmic reticulum 
(ER) via the translocon sec61β. The receptor transports to the inner nuclear membrane 
through movement along the ER/outer nuclear membrane via membrane-bound importin-
β and through the NPC.  
 
 
2. The INFS pathway; integrative nuclear FGFR-1 signaling. The FGFR-1 has an atypical 
transmembrane domain containing short stretches of hydrophobic amino acids interrupted 
with hydrophilic amino acids. Upon stimulation it detaches from the plasma membrane 
and releases into the cytosol [254]. It translocates into the cell nucleus via soluble 
importin-β. However, the interaction to importin-β is unclear as FGFR-1 lacks a NLS 
sequence.  
 
These two pathways were proposed after treating cells with digitonin, thereby washing away 
cytosolic proteins, and studying the cellular localization of EGFR/ErbB-2 and FGFR-1 [252]. 
The suggestion of membrane-bound EGFR and ErbB-2 translocation is further supported by 
studies showing that they are associated with the endosomal marker EEA1 (early endosomal 
antigen 1) in vicinity of the nuclear envelope or inside the nucleus [238, 255]. Additional reports 
have shown that nuclear EGFR transportation is associated with HSP70 and MUC-1, suggesting 
that those proteins could interact with the transmembrane domain of the EGFR [251, 256].  
 
Further, one can speculate in a third pathway represented by ErbB-3 as its nuclear translocation is 
neither clathrin nor caveolin-dependent. Instead, nuclear ErbB-3 in prostate cancer cells is 
dependent on macropinocytosis; when treating the cells with inhibitors of macropinocytosis 
nuclear ErbB-3 transportation is inhibited [257]. 
 
Nuclear localization signal has been found in all of the receptors belonging to the ErbB family 
[247, 249, 255, 258] but not in e.g. the FGFR-1 and the IGF-1R. It is speculated that they enter 
the nucleus with proteins that do have a NLS. There have also been studies pointing to the 
existence of multi-partite NLS which would not be detected when running prediction programs 
based on only the protein sequence [259]. 
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1.8.2 Biological functions 
 
The biological functions of nRTKs are slowly starting to unravel as more investigations are being 
conducted. The EGFR is one of the most well studied receptors and in 2001, Lin et al. 
demonstrated nEGFR’s role as a co-activator in gene transcription [237]. Several following 
studies confirmed this finding and nEGFR affects transcription of cyclin D1 [237], iNOS [260], 
COX-2 [261], Aurora-A [262], c-Myc [263], B-Myb [264], thymidylate synthase [265] and BCRP 
[266]. Transcriptions of these genes have further demonstrated to take place via nEGFR-binding 
to various transcription factors, such as STAT3/5, RNA helicase A (RHA) and E2F1 (Figure 10) 
[267, 268].  
 
 
Figure 10. Schematic representation of nEGFR as a co-activator in gene transcription and its target genes [268]. Re-
printed with permission from BioMed Central. 
 
Further, nuclear EGFR is associated with DNA replication and repair through interactions with 
PCNA and DNA-PK. Proliferation cell nuclear antigen (PCNA) protein binds to DNA and plays 
a pivotal role in DNA replication and damage repair [269]. Nuclear EGFR phosphorylates PCNA 
at tyrosine 211, which increases PCNA’s binding to chromatin and its stability and thereby 
increasing cell proliferation [270]. By using a specific PCNA phosphor-tyrosine 211 antibody a 
correlation between both nEGFR as well as poor overall survival is observed in primary breast 
cancer tumors [270]. The DNA-dependent protein kinase (DNA-PK) is a serine/threonine protein 
kinase and it is a crucial component of the DNA double-strand break (DSB) repair machinery. 
Dittmann et al. demonstrated that upon ionization radiation of bronchial carcinoma cells, EGFR 
rapidly translocates into the nucleus where it associates with DNA-PK followed by increased 
activity of DNA-PK. When blocking nEGFR by pretreatment of cells with cetuximab, the activity 
of DNA-PK as well as its ability to interact with DNA binding complexes decreases [271]. 
 
FGFR-1 is another receptor whose nuclear function has been studied relatively well. Several 
studies have presented nFGFR-1 as a mediator in neuronal differentiation, in vivo. During 
proliferation of brain neural stem/progenitor cells FGFR-1 is mainly located in the plasma 
membrane, but as the cells exit the cell cycle FGFR-1 accumulates in the nucleus. The receptor 
remains nuclear during differentiation and migration of the cells from the subventricular zone to 
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target brain regions [272-274]. This proposes a role of nFGFR-1 in neurogenesis and could 
potentially be a new target for neurodegenerative disorders. 
 
The first study where nIGF-1R was identified demonstrated that the receptor associates with 
chromatin and that it could, as shown by reporter assays, increase transcription [86]. The 
following study presenting nIGF-1R was published just months later by Aleksic et al. and by 
immunoprecipitation and immunofluorescence they showed that nuclear IGF-1R associates with 
histone H3 and RNA polymerase II respectively [275]. Further, nIGF-1R binds to and induces 
IGF-1R gene promoter activity. Interestingly, the IR also binds to the IGF-1R gene promoter, but 
is suggested to inhibit IGF-1R transcriptional activity [181]. More recently, Zhang et al. 
demonstrated the importance of the IGF-1R SUMOylation in proliferation; the IGF-1R SUMO-1 
mutant, unable to translocate into the nucleus, has a lower proliferation rate than the wild type 
receptor [276]. An interesting study published by Aslam et al. showed that rhabdomyosarcoma 
cells (derived from a transgenic mouse model) that are initially high in cell surface IGF-1R 
expression show greater nIGF-1R after just one cell cycle compared to cells with low cell surface 
IGF-1R. Further, it was demonstrated that high expression of nIGF-1R results in an increase 
tumorigenic phenotype to murine alveolar rhabdomyosarcoma cells [277]. 
 
My first project presented in this thesis aimed at further investigating the functions of nIGF-1R. 
 
1.8.3 Clinical implications of nIGF-1R and nEGFR in cancer 
 
The anti-IGF-1R therapy era started off with huge optimism, but as the results from many clinical 
trials were analyzed it has changed to being a great disappointment. However, in unselected 
patient groups there are subgroups that strongly benefit from anti-IGF-1R therapy and today 
researchers urge for finding clinical biomarkers to identify those patient groups, alternatively 
starting to use anti-IGF-1R in combination with other cancer drugs [105, 278]. There are studies 
suggesting that nIGF-1R might be a good biomarker for identifying those patients.  
 
The first study investigating the clinical relevance of nIGF-1R demonstrates that nuclear IGF-1R 
is present in many different cancers including renal cell carcinoma (RCC), prostate cancer, 
adenocarcinomas and pancreatic cancers. The nIGF-1R expression in 195 clear cell RCCs were 
investigated and nIGF-1R was detected in 94 samples and high levels of nIGF-1R correlates with 
shorter survival [275]. 
 
Another study included 16 patients diagnosed with soft tissue sarcomas, Ewing sarcoma or 
osteosarcoma and treated with IGF-1R antibody. Tumor samples were analyzed by 
immunohistochemistry for IGF-1R expression and subcellular localization. In nine samples, 
exclusive nIGF-1R was observed, three samples showed nuclear and cytoplasmic IGF-1R 
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staining and the remaining four samples showed exclusive cytoplasmic IGF-1R localization. 
Patients with exclusive nuclear staining had a significant superior PFS (10.1 - 
months vs. 1.6 months) and OS (28.3 months vs. 6.6 months) as compared to the group with 
nuclear and cytoplasmic or cytoplasmic IGF-1R, suggesting that nIGF-1R might be a biomarker 
for sarcoma patients that will benefit from IGF-1R antibody treatment [279]. Another study 
included 88 patients with synovial sarcomas were all of them underwent surgery, 56% adjuvant 
radiotherapy and 65% adjuvant chemotherapy. Nuclear IGF-1R was identified by 
immunohistochemistry in 21 patients. Five patients had exclusive nIGF-1R staining and 16 
patients had both cytoplasmic and nuclear IGF-1R staining. The analysis showed that nIGF-1R 
expression was negatively correlated with OS; the 5-year OS was 63% for patients with 
positive nIGF-1R expression and 73% in negative patients (p = 0.05) [280]. 
 
It has also been suggested that nIGF-1R might play a role in gefitinib resistance. Bodzin et al. 
demonstrated in the gefitinib-resistant cell line hepatocellular carcinoma Mahlavu cells, that there 
is a strong increase in both IGF-1R activation as well as nuclear translocation upon gefitinib 
treatment [281]. 
 
Several groups have investigated the correlation between nuclear EGFR and the clinical outcome 
in many different cancers. High levels of nEGFR are associated with poor OS and clinical 
aggressiveness in e.g., breast cancer, ovarian cancer, gallbladder cancer and NSCLC [282-286]. 
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2. AIMS OF THESIS 
 
The general aims of this thesis were to investigate the functional effect of nuclear IGF-1R and its 
mechanism for nuclear translocation. We also wanted to explore if other RTKs are SUMOylated 
and decided to focus on the epidermal growth factor receptor. 
 
More specifically, the aims of the three projects presented in this thesis are: 
 
I. To investigate the role of nuclear IGF-1R as a co-activator of LEF-1/TCF 
transcription in the Wnt/β-catenin signaling pathway. 
 
II. To uncover the mechanism by which IGF-1R is translocated into the nucleus. 
 
III. To elucidate EGFR SUMOylation and what the function of SUMO-1 modified EGFR 
is.  
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3. RESULTS AND DISCUSSION 
3.1 PAPER I 
 
Nuclear IGF-1R is a transcriptional co-activator of LEF-1/TCF 
 
When our group first discovered nuclear IGF-1R (nIGF-1R) it was revealed that nIGF-1R binds 
to putative enhancer regions of genomic DNA and drives transcription as shown by gene reporter 
assays [86]. IGF-1 and Wnt signaling have both demonstrated to result in nuclear translocation of 
β-catenin, which in turn binds to transcription factors of the lymphoid enhancer factor/T cell 
factor/ (LEF/TCF) family [177]. Based on these studies we hypothesized that nuclear IGF-1R has 
a more direct impact on LEF-1 transcription.  
 
We first demonstrated that IGF-1R binds to both β-catenin and LEF-1 in the cell nucleus in the 
following three cell lines; DFB (melanoma), H1299 (NSCLC) and HeLa (cervical). It has 
previously been described that nIGF-1R is dependent on IGF-1 stimulation and we found that this 
is also the case for the IGF-1R—LEF-1 association.  
 
Stimulation with IGF-1 causes nuclear translocation of IRS-1, which is required for IGF-1-
mediated nuclear translocation of β-catenin [287]. Next we addressed whether or not IGF-1R—
LEF-1 association is dependent on IRS-1. The nuclear translocation of IGF-1R had previously 
been speculated to be dependent of IRS-1, seeing as IGF-1R lacks a conserved NLS, whilst IRS-1 
has two conserved NLS sites [288]. To assess the importance of IRS-1 we used the mouse 
fibroblasts cell line, R-ΔIRS1, which expresses human IGF-1R with a mutation in the IRS-1 
binding site (Y950F). The R-ΔIRS1 cells were subjected to subcellular fractionation and our 
results show that the cells express nuclear IGF-1R; demonstrating that nuclear IGF-1R is 
independent of IRS-1.  In addition, the IGF-1R-ΔIRS1 mutant associates with LEF-1 as 
determined by immunoprecipitation experiments and based on those results we concluded that 
IGF1R-LEF1 binding is independent of IRS-1. Upon Wnt/IGF activation, β-catenin translocates 
into the nucleus and creates an active transcriptional complex with LEF1/TCF by displacing the 
transcriptional inhibitor Groucho and CBP by binding to the N-terminal of LEF-1 [160]. To 
assess if β-catenin is required for IGF-1R—LEF-1 association we transfected H1299 cells with 
mock, Myc-wt-LEF-1 and Myc-Δβ-cat-LEF-1, the latter being a LEF-1 mutant lacking the β-
catenin binding site. Surprisingly, this mutant did not affect IGF-1R—LEF-1 association, neither 
was it affected by β-catenin knockdown nor overexpression.  
 
Next we sought to investigate if IGF-1R can activate cyclin D1 and axin2; two target genes of 
LEF-1. To do so, we used the IGF-1R triple sumo mutant (TSM), mutated in lysine residues 
1025, 1100 and 1120. TSM impairs IGF-1R SUMOylation and the receptors ability to translocate 
into the nucleus, but it does not affect the canonical IGF signaling through PI3K and MAPK 
pathways [86]. SKUT-1 cells – lacking endogenous IGF-1R – were transfected with mock, IGF-
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1R or TSM and the mutant does not associate with LEF-1. IGF-1R and LEF-1 associations are 
also solely nuclear as visualized by in situ PLA. By using promoter-luciferase cyclin D1 and 
axin2 reporter constructs in SKUT-1 cells, transfected with IGF-1R or TSM, we found that upon 
IGF-1R overexpression the activity of cyclin D1 and axin2 promoters increase by 17% and 22% 
respectively, compared to mock. However, in cells overexpressing TSM, the cyclin D1 and axin2 
promoter activity decreases with 7% and 20%, respectively, compared to mock transfections. 
This data suggests that nIGF-1R increases LEF-1 downstream activity. We also observed an 
increase at the protein level of cyclin D1 and axin2 when transfecting H1299 cells with IGF-1R 
compared to mock and TSM transfections. 
 
Finally, we showed that nIGF-1R binds to genomic cyclin D1 promoter. This was demonstrated 
by chromatin IP (ChIP)-qPCR. Chromatin fragments from DFB and HeLa cell lysates were 
pulled down with IGF-1R antibody and analyzed by qPCR to detect genomic regions containing 
the TCF/LEF-1 binding element of the cyclin D1 promoter. The binding of IGF-1R to LEF-1-
binding site in the cyclin D1 promoter is nearly six-fold higher in DFB and 12-fold higher in 
HeLa cells compared with a non-specific control region. Further, H1299 cells were transfected 
with empty vector, IGF-1R or TSM, followed by ChIP-qPCR. IGF-1R transfected cells have a 
120-fold increase in LEF-1-binding site in the cyclin D1 promoter compared to empty vector and 
TSM transfected cells. This suggests that nuclear IGF-1R binds to the LEF-1 binding site of the 
cyclin D1 promoter.  
 
Our data suggests that upon nuclear translocation of the IGF-1R, the receptor binds to the LEF-1 
transcription factor in the nucleus, leading to elevated protein levels of cyclin D1 and axin2. This 
study proposes an additional function of the IGF-1R, besides its classical tyrosine kinase activity. 
 
3.2 PAPER II 
 
Nuclear translocation of IGF-1R via p150
Glued
 and an importin-β/RanBP2-dependent 
pathway in cancer cells 
 
This study aimed at unravelling the transportation mechanism of the IGF-1R; how the receptor 
travels from the plasma membrane, across the nuclear envelop and further into the nucleus.  
 
Previously, it was revealed that nuclear IGF-1R is dependent on clathrin-mediated endocytosis, 
rather than caveolin-raft endocytosis [275]. We hypothesised that the IGF-1R is transported as a 
membrane-bound entity via vesicle-mediated transportation. Firstly, we found that the EEA1 
protein, important in clathrin-dependent internalization, is co-localized with the IGF-1R, both in 
the cytoplasm and inside the cell nucleus, suggesting that the receptor might exist in the nucleus 
in a vesicle formation derived from the endosomal compartment, or alternatively, that the 
endosomes have fused with the nuclear membrane. 
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Knowing that microtubules (MT) are considered to be the ―highways‖ for long distance vesicular 
transportation, we explored the possibility that the IGF-1R is retrogradely transported inside the 
cell along microtubules. MT-structures were disrupted by the drug colchicine, followed by 
subcellular fractionation. Colchicine treated cells do not show nuclear accumulation of IGF-1R 
after IGF-1 stimulation.  Next we investigated if MT-associated translocation is mediated through 
the dynactin complex, a multi-subunit complex which interacts with EEA1-positive vesicle [289]. 
Indeed, the largest subunit of dynactin, p150
Glued
, associates with IGF-1R in in situ PLA as well 
as immunoprecipitations. When we disrupted dynactin by either p150
Glued
 knockdown with 
siRNA or overexpressing dynamitin (also a member of dynactin and well documented to inhibit 
dynein/dynactin transportation if overexpressed in cells), there is a significant decrease in nIGF-
1R by nearly 50% compared to control transfected cells. This data indicates that IGF-1R is 
transported to the nucleus via dynactin-mediated transfer along microtubule. 
 
As mentioned in the introduction, for several RTKs it has already been established that their 
nuclear translocations are dependent on importin-β interaction. This is also the case for IGF-1R. 
First we presented that IGF-1R and importin-β associates and that it occurs after interacting with 
dynactin. This was based on the results showing that the IGF-1R—importin-β association 
diminishes after dynamitin overexpression. In line with previous reports we demonstrated a 
decrease in nIGF-1R after importin-β siRNA knockdown. This result was further confirmed by 
overexpression of the Ran mutant, RanQ69L, which inhibits the essential GTP hydrolysis in 
importin-β-mediated nuclear translocation. 
 
SUMO-1 modification of the IGF-1R is a prerequisite for its nuclear translocation. Next we 
addressed the role of SUMOylation in more detail. We decided to focus on the nucleoporin 
RanBP2, one of the known SUMO E3 ligases that interacts with importin-β. A study from Giri et 
al. has demonstrated that RanBP2 is involved in the nuclear translocation of ErbB-2 [238]. Using 
in situ PLA we demonstrated that RanBP2 and IGF-1R co-localize around the nuclear brim. 
These results were confirmed by immunoprecipitation, where after RanBP2 pull-down, the sizes 
of the IGF-1R bands are equal to the size of SUMOylated IGF-1R. To explore if RanBP2 is a 
potential SUMO E3 ligase for IGF-1R, cells were transfected with the E3-domain of RanBP2. 
Indeed, the IGF-1R SUMOylation increases, but does not affect nuclear IGF-1R, which could be 
due to that the RanBP2E3 protein no longer localizes at the nuclear brim, but in the cytoplasm. 
RanBP2 knockdown by siRNA results in a strong reduction in nIGF-1R; 70% less nIGF-1R in 
knockdown cells compared to control.  
 
Several studies have reported that SUMO modifications affect protein stability. To investigate the 
stability of SUMOylated IGF-1R we used the IGF-1R SUMO mutant, TSM. Wild-type IGF-1R 
and TSM were transfected in IGF-1R deficient SKUT-1 cells, followed by cycloheximide 
treatment to block newly synthesized protein. In fact, TSM is degraded faster than wild-type 
receptor. To further relate SUMO-1’s role in IGF-1R stability with RanBP2 as the E3 ligase, cells 
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were treated with cycloheximide after knockdown of RanBP2. In RanBP2 knockdown cells the 
IGF-1R is degraded dramatically faster. 
 
Knockdown of RanBP2 gives a greater effect on nIGF-1R, than knockdown of either dynactin-
mediated transportation or importin-β. It could of course be due to better silencing efficiency, or 
it could be because RanBP2 has a dual role in IGF-1R translocation; it mediates transportation 
through the NPC, as well as stabilizes the receptor. It can also be speculated that IGF-1R 
SUMOylation might function as a sorting mechanism; SUMO-1 modified receptors will be 
targeted for nuclear import, whilst un-SUMOylated receptors will be targeted for degradation. 
Future studies should investigate if TSM is ubiquitylated to a higher degree than the wild-type 
receptor.  
 
Further, we demonstrated that the RanBP2—IGF-1R association is dependent on importin-β. 
Knockdown of importin-β or overexpression of the importin-β-IA/YA, a mutant which 
previously has been shown to impede importin-β — RanBP2 association, results in a decrease in 
RanBP2—IGF-1R association. Finally, we showed that nIGF-1R pathway is IGF-1 dependent. 
After 30 minutes of IGF-1 stimulation there is a maximum association between IGF-1R —
p150
Glued
 and between IGF-1R— importin-β. Interestingly, no change was observed between 
IGF-1R—RanBP2 association; this interaction is stable even after serum starvation. Thus, this 
data suggests that IGF-1R bound to RanBP2 might act as an intra-cellular reserve. 
 
In summary, the suggested pathway presented in this work is as follows; Plasma membrane-
bound IGF-1R internalizes in EEA1-positive vesicles upon ligand stimulation. The vesicle-bound 
IGF-1R transports to the nuclear brim along microtubules via dynactin complex. Importin-β 
further transfers IGF-1R to RanBP2 which mediates transportation through the NPC (Figure 11). 
 
It still needs to be elucidated how importin-β binds to the IGF-1R seeing as it lacks a conserved 
NLS. It could still be a direct interaction through a non-canonical NLS sequence, or the 
association occurs through a yet undefined protein. It is plausible that the proposed pathway is 
also utilizing the so-called INTERNET pathway, involving retrograde transportation to Golgi and 
the endoplasmic reticulum, via the translocon sec61β. The nIGF-1R pathway has many 
similarities to the one for EGFR and ErbB-2, e.g., they are interacting with EEA1 and importin-β. 
It has also been reported that the ER can itself slide along microtubules, and this was visualized 
by following the sec61β translocon [290]. These microtubules were also nocodazole-resistant due 
to acetylation, which is very interesting as our group have struggled to see a difference in nIGF-
1R after nocodazole treatment (unpublished data). Further studies need to be carried out to 
connect the IGF-1R pathway with the ER-dependent pathway via sec61β. 
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Figure 11. Schematic representation of nuclear translocation of IGF-1R. 
 
3.3 PAPER III 
 
Nuclearly localized epidermal growth factor receptor is SUMOylated 
 
After the initial study showing that the IGF-1R is SUMOylated, it has been reported that the IR 
and the ErbB-4 are also SUMO modified. This project aimed at investigating EGFR 
SUMOylation and its potential function.  
 
Here, as the first group, we demonstrated that the EGFR is indeed SUMO-1 modified in three 
tested cell lines; H1299 (NSCLC), HCT116 (colon cancer) and HeLa (cervical cancer). This 
interaction is mainly nuclear, in contrary to the IGF-1R SUMOylation which is perinuclear, 
indicating that it is likely that the function of EGFR SUMOylation is different compared to the 
one reported for IGF-1R. 
 
The EGFR contains 66 lysine residues, all of which could be a potential target for SUMO-1. To 
be able to study the functional importance of EGFR SUMOylation we performed multiple mass 
spectrometry analyzes in order to identify which lysine residue/s is/are SUMOylated. We used 
the porcine aortic endothelia (PAE) cell line, which does not express endogenous EGFR, ErbB-2 
and ErbB-3. PAE cells were transfected with EGFR and SUMO-1. SUMO-1 generates a 19 
amino acid side chain when attached to the receptor. In the first analysis, we used MALDI-TOF 
peptide mass fingerprints and identified four peptides that are SUMO-1 modified, corresponding 
to lysine residues 37, 129, 399 and 949 of the EGFR. However, this method is restricted to only 
identifying peptides smaller than 5000 Da. In addition, we used liquid chromatography tandem 
mass spectrometry, and a T95R mutation on SUMO-1 was introduced, allowing us to get a 
specific glycine-glycine signature on the SUMOylated peptides. This method revealed one 
additional lysine residue; K328 as well as confirming lysine 37.  
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Five EGFR-constructs were created using site-directed mutagenesis; generating lysine to arginine 
mutants in the suggested sites above. These five single mutants do not block EGFR 
SUMOylation, which is to be expected, since the remaining four un-mutated lysine residues can 
still be targeted by SUMO-1. This result tells us that the EGFR is either mono-SUMOylated, but 
when only mutating one residue at a time, the receptor will be SUMOylated in a compensatory 
manner in any of the other four sites, or that the EGFR is modified by several SUMO-1 proteins 
at the same time. For future studies, all five identified residues need to be mutated.  
 
Since, only one lysine came up as a hit between the two mass spectrometry methods we decided 
to focus on that one; i.e. lysine 37. EGFR-K37R mutant did not alter the EGFR downstream 
activation by EGF. Neither did EGFR-K37R influence the stability of the receptor nor its 
capability to undergo nuclear translocation. As the EGFR SUMOylation is only visualized in the 
nucleus in endogenous expressing cells, it is very likely that the SUMOylation occurs first after 
nuclear translocation. Thereby, it would not be dependent on RanBP2 as the SUMO E3 ligase as 
in the case of the IGF-1R. In fact, we cannot detect EGFR-RanBP2 association by 
immunoprecipitation, but with several of the PIAS E3 ligases (data not shown).  
 
To address if EGFR-K37R has any functional outcome of nEGFR-mediated responses, we 
decided to investigate if the mutant affects c-Myc and cyclin D1 expression; two genes whose 
transcription is induced by nEGFR. PAE cells were transiently transfected with mock, EGFR or 
EGFR-K37R. Both c-Myc and cyclin D1 protein expressions are significantly reduced in the 
EGFR-K37R mutant compared to wild-type receptor. Further, by performing luciferase-promoter 
assays we revealed that the c-Myc promoter activity, as well as the cyclin D1 promoter activity, 
are significantly reduced in the mutant compared to wild-type EGFR.  
 
Even though there are several studies reporting that SUMO-1 modification can increase 
transcription, it is more commonly shown to function as a repressive mechanism. It could be that 
the K37R mutants permit stronger SUMOylation by any of the remaining four suggested 
residues, thereby reducing transcriptional activity or that it is in fact SUMOylation of lysine 37 
that induces transcription. Future studies should investigate if EGFR-K37R affects the binding to 
the transcription factors STAT3 and RNA helicase A, which are demonstrated to associate with 
nEGFR-dependent transcription of c-Myc and cyclin D1 respectively. Nuclear EGFR is 
associated with DNA repair and it would be interesting to investigate its relation to EGFR 
SUMOylation.  
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3.4 GENERAL DISCUSSION AND CONCLUDING REMARKS 
 
Initially, the IGF-1R targeted therapy started out very promising; showing solid anti-tumor 
effects in vitro as well as in animal models, but as the clinical trials took off and the result from 
the patient outcome returned, the enthusiasm was replaced with disappointment. Today, research 
groups are trying to identify biomarkers to predict patient groups that will respond to anti-IGF-1R 
therapy. To isolate new biomarkers, we have to go back to the lab bench and proceed with basic 
research to unravel the yet undefined mechanisms in IGF-1R cellular response. This thesis aims 
at just that. This group has previously identified nuclear IGF-1R and based on research carried 
out by several other groups, nIGF-1R has a significant role in cancer therapy; both as a 
prognostic factor, but it also has diagnostic value. Therefore it is important to understand the 
basic underlying functions and mechanisms of nuclear IGF-1R, which are presented in project I 
and II and the results can be summarized as follows: 
 
 Nuclear IGF-1R associates with the LEF-1/TCF transcription factor and acts as co-
activator and induces transcription of genes such as Axin2 and cyclin D1, two genes 
shown to be important in cancer biology. In addition, IGF-1R—LEF-1 interaction is 
independent of β-catenin and IRS-1. 
 
 Upon IGF-1 stimulation IGF-1R undergoes nuclear translocation. This transportation 
is dependent on transport along microtubules through binding to the dynactin 
complex. Its nuclear import across NPC is mediated through importin-β/RanBP2. 
IGF-1R SUMOylation is also important for the stability of the receptor.  
  
With regards to EGFR SUMOylation, this is just an initial study and more thorough studies need 
to be carried out in the quest of fully understanding the mechanism and cellular response of 
SUMO-1 modified EGFR. Although this study does not provide a complete picture of the EGFR 
SUMOylation it tells us that: 
 
 EGFR SUMOylation is mainly nuclear and five targeted lysine residues are proposed; 
K37, K129, K328, K399 and K949. By blocking SUMOylation of one site, K37, it affects 
EGFR-dependent transcription of c-Myc and cyclin D1.  
 
These three projects together imply that SUMOylation of RTKs might be a very important 
modification that influences their recently identified nuclear functions. Future direction is to 
identify the clinical importance of IGF-1R and EGFR SUMOylation. Could RTK SUMOylation 
be a new biomarker? Could SUMOylation be the missing link in finding patients responsive to 
anti-IGF-1R therapy? Could identified SUMO sites be potential drug targets? We will only have 
the answers by continuing to investigate the role of SUMOylation in RTKs.  
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